PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084696
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084696
MedTech & Biopharma Device CMO/CDMO Market is estimated to be valued at USD 110,227.2 Mn in 2026 and is expected to reach USD 271,758.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 110,227.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.80% | 2033 Value Projection: | USD 271,758.5 Mn |
The global MedTech & biopharma device CMO/CDMO market includes contract development and manufacturing services for medical devices, diagnostics, drug-device combination products, and drug delivery devices with high growth and innovation, as well as contract development and manufacturing services for devices and medical and healthcare applications. By functioning as outsourcing partners, CMOs/CDMOs help client companies design, engineer, provide and integrate regulatory, manufacturing, packaging and logistics.
The need to control operational and product development expenses, speed product to market, gain market access for new innovative products and leverage specialized know how is encouraging pharmaceutical, medical device, and biopharmaceutical industries to seek an outsourced product design, development and manufacturing partner solution. Increased usage of autoinjector devices and biologics delivery devices, wearable medicals devices, and associated healthcare devices will require partnerships with strategically positioned CMOs/CDMOs throughout the life science industry, including drug development and delivery device and drug device combinations.
The global MedTech & biopharma device CMO/CDMO market is driven by the rising level of outsourcing of device development and manufacturing functions. Adoption of drug device combination products, biologics delivery devices and connected devices for medtech devices is promoting life sciences players to attain CMO/CDMO competency to optimize time-to-market, manufacturing and cost efficiency.
However, a number of constraints are present in the market, such as stringent regulatory barriers, tedious validation process, and high-quality protection cost. These market limitations coupled with the bottlenecks in the supply chain and the limited capacity for niche manufacturing services pose hurdles to the market advancement. Nevertheless, increasing adoption of innovative drug delivery devices and wearable healthcare technologies as well as shift toward strategic outsourcing by emerging life sciences organizations will offer new opportunities for growth in MedTech & biopharma device CMO/CDMO market.